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Abstract
Familial hypercholesterolemia (FH) is a common autosomal codominant disease with a frequency of 1:500 individuals in its
heterozygous form. The genetic basis of FH is most commonly mutations within the LDLR gene. Assessing the pathogenicity
of LDLR variants is particularly important to give a patient a definitive diagnosis of FH. Current studies of LDLR activity
ex vivo are based on the analysis of 125I-labeled lipoproteins (reference method) or fluorescent-labelled LDL. The main
purpose of this study was to compare the effectiveness of these two methods to assess LDLR functionality in order to
validate a functional assay to analyse LDLR mutations. LDLR activity of different variants has been studied by flow cytometry
using FITC-labelled LDL and compared with studies performed previously with 125I-labeled lipoproteins. Flow cytometry
results are in full agreement with the data obtained by the 125I methodology. Additionally confocal microscopy allowed the
assignment of different class mutation to the variants assayed. Use of fluorescence yielded similar results than 125I-labeled
lipoproteins concerning LDLR activity determination, and also allows class mutation classification. The use of FITC-labelled
LDL is easier in handling and disposal, cheaper than radioactivity and can be routinely performed by any group doing LDLR
functional validations.
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Introduction
Familial hypercholesterolemia (FH; MIM #143890) was the
first genetic disease of lipid metabolism to be characterized and is
mechanistically linked to the pathogenesis of coronary heart
disease (CHD) [1]. FH is an autosomal codominant disorder
characterized by increased plasma LDL cholesterol, tendon
xanthomas, deposits of cholesterol in peripheral tissues and
accelerated atherosclerosis, leading to premature coronary heart
disease (CHD) [1]. FH has a heterozygous frequency of 1:500 and
a homozygous frequency of 1:1,000,000, with a prevalence of
1:200,000 for compound heterozygous [2]. FH is mainly due to
mutations in the LDL receptor (LDLR; MIM #606945) gene,
which is responsible for the uptake of LDL particles into cells [1].
To date, more than 1,300 different mutations in the LDLR gene
have been identified worldwide [3] but not all of them have been
proved to affect receptor activity. Mutations have been assigned to
different classes depending on their effect: class 1 mutations result
in no detectable LDL receptor protein [4]; class 2 mutations cause
either complete (class 2a) or partial (class 2b) block of transport of
the LDL receptor from the ER [5]; class 3 mutations result in
defective LDL binding [6]; class 4 mutations cause defective
clustering in clathrin coated pits [7,8] and class 5 mutations result
in recycling defective receptors [9]. In order to provide a definite
and complete diagnosis of FH, LDLR mutations should be
assessed both for activity and class type mutation.
In a recently reported study, in silico analysis of 443 described
missense variants predicted a loss of LDLR activity in 89% of the
described variants using at least one in silico method [10].
However, it is well recognized that in silico software has several
limitations and has to be used with caution [11]. Functional
validation of these LDLR variants must be assessed in order to
identify which mutations lead to a functional loss of receptor
activity. Once characterized, unequivocal genetic diagnosis of FH
is possible, allowing the implementation of adequate treatment
(either early initiation or intensification) to reduce the increased
cardiovascular risk characteristic of these patients. The early
identification and treatment of FH patients is especially important
for young patients in whom the physical stigmata are not yet
developed and so CHD can be prevented. Current methodologies,
PLOS ONE | www.plosone.org 1 November 2014 | Volume 9 | Issue 11 | e112677
which determine LDLR functionality ex vivo, are based on the use
of radioactivity or flow cytometry. LDL uptake and degradation of
125I-labeled LDL is commonly determined in radioactivity-based
methods, and very similarly, binding and uptake of LDL are
determined by flow cytometry when using fluorescent-labelled
LDL [6,12–17]. Both methods are used indistinctly, probably
depending on the research laboratory facilities or because there is
a traditional used methodology in the laboratory.
To compare the suitability of both techniques in the determi-
nation of LDLR activity with regard to sensitivity, reproducibility
and practical considerations, we have conducted an inter-
laboratory comparative study. Data obtained by 125I assays in
one of the laboratories [11] have been compared with data
obtained by FITC-labelled LDL in another laboratory. We have
also analysed whether the use of FITC-labelled LDL and flow
cytometry is a reliable assay for the functional characterization of
LDLR variants and whether the advantages of the fluorescence
assay can be extended to the assignment of LDLR class type
mutation. In both type of experiments CHO-ldlA7 cells transfect-
ed with the plasmids encoding wild-type (wt) or LDLR variants
p.Val429Leu (c.1285G.C), p.Trp490Arg (c.1468T.C),
p.Ser648Pro (c.1942T.C), p.Pro685Ser (c.2053C.T) and
p.Val859Met (c.2575G.A) have been used. Confocal laser
microscopy was used to determine the cellular localization, class
type mutation and biological activity of the mutant LDLR.
Materials and Methods
Variant nomenclature
For sequence analysis the reference sequence used was
NM_000527.4 and cDNA numbering was considered following
the Human Genome Variation Society nomenclature, with
nucleotide c.1 being A of the ATG initiation codon p.1 [18,19].
In silico analysis
The predicted effects of LDLR alterations were assessed using
the following open access software: PolyPhen-2 [20], Sorting
Tolerant From Intolerant (SIFT) [21], Consensus Deleteriousness
score of missense SNVs (Condel) [22], Mutation taster [23],
Grantham Score [24] and PhyloP [25]. The PolyPhen-2 programs
give predictions of ‘‘Probably Damaging’’, ‘‘Possibly Damaging’’
and ‘‘Benign’’. The programs SIFT and CONDEL predict
whether an amino acid substitution would be ‘‘Deleterious’’ or
‘‘Neutral’’. The program Mutation Taster gives a prediction of
‘‘Disease Causing’’ or ‘‘Polymorphism’’. The program Grantham
Score predicts, in a numerical form, whether an amino acid
substitution is: conservative (0–50), moderately conservative (51–
100), moderately radical (101–150), or radical ($151). The
program PhyloP (phylogenetic p-value) gives a prediction in a
numerical form between 214.1 and 6.4 (the higher the value the
most conserved the nucleotide is between species).
Site-directed mutagenesis
Individual point mutations leading to p.Val429Leu,
p.Trp490Arg, p.Ser648Pro, p.Pro685Ser and p.Val859Met
LDLR variants were generated as described before [11]. Presence
of the desired nucleotide alteration was confirmed by PCR and
restriction enzyme digestion of the appropriate fragments and the
integrity of the remaining LDLR cDNA sequence of all constructs
was verified by direct sequence analysis.
Expression of LDLR proteins in vitro
LDLR-deficient Chinese hamster ovary (CHO) cell line ldlA7
(CHO-ldlA7) (kindly provided by Dr. Monty Krieger, Massachu-
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setts Institute of Technology, Cambridge, MA) was cultured in
Ham’s F-12 medium supplemented with 5% FBS, 2 mM L-
glutamine, 100 units/mL penicillin, and 100 mg/mL streptomy-
cin. CHO-ldlA7 cells were plated into 24 well culture plates, and
transfected with plasmids carrying the LDLR mutations using
Lipofectamine LTX and Plus Reagent (Invitrogen) according to
the manufacturer’s instructions. Transfected cells were maintained
in culture during 48 h to achieve maximal LDLR expression.
Western blot analysis
Cell lysates were prepared, protein concentration determined,
and fractionated by electrophoresis on non-reducing 8.5% SDS-
PAGE for semi-quantitative immunoblotting. Membranes were
immunostained with rabbit polyclonal anti-LDLR antibody
(1:2000) (Cayman Chemical, Cat. No. 10007665) for 16 h at
4uC and rabbit polyclonal IgG anti-GAPDH antibody (1:1000)
(Santa Cruz Biotechnology, Cat. No. SC-25778) for 1 h at room
temperature and counterstained with a horseradish peroxidase-
conjugated anti-rabbit antibody (Cell Signalling, Cat. No: 7074s).
The signals were developed using SuperSignal West Dura
Extended Substrate (Pierce Biotechnology, Rockford, IL, USA).
ChemiDoc XRS (Bio-Rad, Hercules, CA, USA) was used to detect
the signals, and Quantity One Basic 4.4.0 software (Bio-Rad) was
used to quantify band intensities. The concentrations of the
antibodies were optimized to achieve low background and a linear
dose-dependent increase in signal intensity. The relative band
intensities for the mature and precursor forms of LDLR protein
expressed for the different constructs was calculated as the ratio
between the LDLR 160 kDa or 130 kDa bands to that of
GAPDH.
Real-time Quantitative PCR
CHO-ldlA7 cells (0.56106) were seeded in 6-well tissue-culture
plates overnight and transfected as described before. 48 h post-
transfection, RNA was harvested from cells using TRIzol Reagent
(Invitrogen), and cDNA was synthesized from 1 mg of RNA using
Affinity Script qRT-PCR cDNA synthesis kit (Stratagene, Agilent
Technologies, USA) according to the manufacturer’s instructions.
The qRT-PCR was performed in triplicates using the Brilliant-III
Ultra Fast SYBR Green QPCR. Primers were purchased from
Integrated DNA Technologies (Cat. No. Hs.PT.58.3621384 for
LDLR and, the primer sequences used to amplify hamster
GAPDH gene were 59-CATGTTCCAGTATGACTCCACTC-
39 and 59-GGCCTCACCCCATTTGATGT-39). Reactions were
performed in the Applied Biosystems 7900HT Fast Real-Time
PCR System, the real-time PCR program consisted of 40 cycles
(95uC for 15 s and 60uC for 1 min) after initial 10 min incubation
Figure 1. Protein and mRNA expression of wt LDLR and LDLR variants in CHO-ldlA7 transfected cells. Cells were transfected with the
corresponding plasmids carrying the mutations of interest, LDLR was overexpressed for 48 h and then (A) protein expression was analyzed by
Western blot, (B) the relative band intensities of both mature and precursor LDLR forms were calculated as the ratio of 160 kDa or 130 kDa LDLR band
intensity to that of GAPDH (C) relative LDLR mRNA expression determined by qRT-PCR (normalised to GAPDH). A representative experiment from
three independently performed assays is shown in (A). The values in (B) and (C) represent the mean of triplicate determinations (n = 3) and (n = 2),
respectively; error bars represent6SD. Levels of significance were determined by a two-tailed Student’s t-test, and a confidence level of greater than
95% (p,0.05) was used to establish statistical significance. *p,0.001 compared to the LDLR wt 160 kDa band and #p,0.001 compared to LDLR wt
130 kDa band using a Student’s t-test.
doi:10.1371/journal.pone.0112677.g001
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at 95uC. Reactions were conducted in triplicate, and expression of
all transcripts relative to GAPDH was determined.
Uptake and degradation of 125I-LDL
LDL catabolism in CHO-ldlA7 cells carrying wt or LDLR
variants was determined by using 125I-labelled LDL as previously
described [12,26]. Each LDLR variant expressing CHO-ldlA7
cells were seeded on day 1 in 12-well plates (26105 cells/dish) in
triplicates to determine the ability of uptake (binding plus
internalization) or degrade 125I-labelled LDL. To achieve maxi-
mum LDLR expression, on day 2 cells were washed and
preincubated for 12 h in growth medium containing 10% (v/v)
lipoprotein-deficient serum (LPDS, Chemicon) and sterols (90 mg/
mL of cholesterol and 9 mg/mL of 25(OH)-cholesterol). On day 3,
cells were washed and incubated for 4 h at 37uC in medium
containing 5% LPDS and different concentrations of 125I-LDL.
LDL uptake, determined at 376C, accounts for both binding and
internalization of LDL particles. Saturable uptake and degrada-
tion of 125I-LDL were determined as the difference in cell-
associated radioactivity (uptake) or the acid-soluble non-iodine
radioactivity in the medium (degradation) between cells incubated
with 125I-LDL in the presence or absence of an excess (1 mg/mL)
of unlabeled LDL, as described before [16,27]. Experiments were
repeated at least twice with triplicate samples for each cell line.
Data is shown as the percentage of maximum obtained for wt
LDLR at 4 h.
Lipoprotein labelling with FITC
LDL was labelled with FITC as previously described [28].
Briefly, LDL (1 mg/mL) in 0.1 M NaHCO3 (pH 9.0) were mixed
with 10 ml/mL of FITC (2 mg/mL in dimethyl sulfoxide). The
mixture was gently mixed by slow rocking at room temperature for
2 h. The unreacted dye was removed by gel filtration on a
sephadex G-25 column equilibrated with PBS EDTA-free buffer.
All fractions were assayed for protein content with bovine serum
albumin as standard (Pierce BCA protein assay, Pierce).
Quantification of LDLR activity by flow cytometry
Transfected CHO-ldlA7 cells were grown in 24 well culture
plates. 48 h after transfection, cells were incubated for 4 h, at
37uC or at 4uC with 20 mg/mL FITC-LDL to determine LDLR
activity or LDL-LDLR binding, respectively. After incubation
with FITC-LDL, CHO-ldlA7 cells were washed twice in PBS-
1%BSA, fixed on 4% formaldehyde for 10 min and washed again
twice with PBS-1%BSA. The quenching of external fluorescence,
which distinguishes internalized from surface-adherent FITC-LDL
particles, can be accomplished with the use of vital dyes such as
Trypan blue [29], which is not able of penetrating intact cell
membranes. This procedure allows to remove extracellular
fluorescence by quenching and to determine the intensity of the
Figure 2. Saturable uptake and degradation of labeled-LDL in
CHO-ldlA7 transfected cells with wt LDLR. (A) saturable uptake of
125I-LDL, (B) saturable degradation of 125I-LDL and, (C) saturable uptake
of FITC-LDL. For analysis of 125I-LDL uptake (binding plus internaliza-
tion) and degradation, CHO-ldlA7 transfected cells expressing wt LDLR
were incubated for 4 h at 37uC with increasing concentrations of 125I-
LDL as indicated. Subsequently, cells were assayed for cell associated
radioactivity (uptake) and degradation of the protein component of
LDL. Values were corrected for non-saturable association or degrada-
tion determined in the presence of an excess of unlabeled LDL (1 mg/
mL). For analysis of FITC-LDL uptake, CHO-ldlA7 transfected cells
expressing wt LDLR were incubated for 4 h at 37uC with increasing
concentrations of FITC-LDL as indicated. 10,000 cells were acquired in a
Facscalibur and values of LDL uptake were calculated as described in
Material and Methods. The values represent the mean of triplicate
determinations (n = 3); error bars represent 6SD.
doi:10.1371/journal.pone.0112677.g002
Fluorescence-Based LDLR Functional Activity
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remaining fluorescent particles inside the cells that is not affected
by the external quencher. Therefore, to determine the amount of
internalized LDL, Trypan blue solution (Sigma-Aldrich, Stein-
heim, Germany) was added to a final concentration of 0.2%
directly to the samples, eliminating the extracellular signal due to
the non internalized LDLR-LDL complexes. Fluorescence inten-
sities were measured by flow cytometry, in a Facscalibur Flow
cytometer according to the manufacturer instructions as previously
described [30]. For each sample, fluorescence of 10,000 events was
acquired for data analysis. All measurements have been performed
at least in triplicate. Uptake efficiency was corrected using the data
of mature protein expression quantified by Western blot and data
is shown as the percentage of maximum obtained for wt LDLR.
Quantification of LDLR expression by flow cytometry
To determine cell surface expression of LDLR by FACS,
transfected CHO-ldlA7 cells grown during 48 h were incubated
with a mouse primary antibody anti-LDLR (1:100; 5 mg/L;
Progen Biotechnik GmbH, Cat. No. 61087) for 1 h, at room
temperature, then, washed twice with PBS-1%BSA and incubated
with a secondary antibody Alexa Fluor 488-conjugated goat anti-
mouse IgG (1:100; Molecular Probes; Cat. No. A-11001). As
negative controls, non transfected CHO-ldlA7 cells or transfected
with the wt LDLR were stained with the same primary anti-LDLR
antibody (Progen Biotechnik GmbH, Cat. No. 61087), which is
negative for CHO-ldlA7 cells and, with mouse IgG2b, kappa
monoclonal [MPC-11]-isotype control (abcam; Cat. No. ab18457)
in identical conditions. As shown in Figure S1, isotype control
antibody has no specificity for CHO-ldlA7 cells transfected or not
with LDLR. For each sample, fluorescence of 10,000 events was
acquired for data analysis. All measurements have been performed
at least in triplicate. LDLR expression efficiency was corrected
using the data of mature protein expression quantified by Western
blot and data is shown as the percentage of maximum obtained for
wt LDLR.
Confocal Laser Scanning Microscopy (CLSM)
CLSM was used to analyze expression of LDLR and
colocalization of LDLR with endoplasmic reticulum (ER). Briefly,
cells grown in coverslips were transfected with the LDLR
containing plasmids and cultured for 48 h, at 37uC in 5% CO2.
Then, the medium was removed and glass slides washed twice with
PBS-1%BSA. For these studies non labelled lipoproteins (20 mg/
mL LDL) were added and cells were incubated at 37uC for
additional 4 h. Cells were fixed with 4% paraformaldehyde during
10 min and washed three times with PBS-1%BSA and permea-
bilized with 1% TritonX-100 for 30 min at room temperature.
Samples were then washed and blocked in PBS-10% FBS for 1 h
and washed in PBS-1%BSA three times. Then, samples were
incubated for 16 h at 4uC with the appropriate primary
antibodies: chicken pAB anti-calreticulin (abcam; Cat. No.
ab18457), and mouse mAB anti-LDLR (Progen Biotechnik
GmbH, Cat. No. 61087) for calreticulin and LDLR colocalization;
and, Rabbit pAB Anti-Apolipoprotein B (abcam; Cat. No.
ab20737) for ApoB-100 and LDLR colocalization; followed by
incubation with the appropriate fluorescent secondary antibodies:
Alexa Fluor 594 Goat Anti-Chicken IgG (Molecular probes; Cat.
No. sc-11042), Alexa Fluor 488 Rabbit Anti-Mouse IgG (Molec-
ular probes; Cat. No. A-11059), Texas Red goat anti-mouse IgG
(Molecular probes; Cat. No. T-862) or Alexa Fluor 488 Goat Anti-
Rabbit IgG (Molecular probes; Cat. No. A-11008). Coverslips
were mounted on a glass slide and samples were visualized using a
confocal microscope (Olympus IX 81) with sequential excitation
Figure 3. Uptake and degradation of labeled-LDL in CHO-ldlA7
transfected cells with wt or different LDLR variants. (A) Uptake
of 125I-LDL, (B) degradation of 125I-LDL and, (C) uptake of FITC-LDL. For
analysis of 125I-LDL uptake (binding plus internalization) and degrada-
tion, CHO-ldlA7 transfected cells expressing wt LDLR were incubated for
4 h at 37uC with 20 mg/mL of 125I-LDL as indicated. Subsequently, cells
were assayed for cell associated radioactivity (uptake) and degradation
of the protein component of LDL. Values were corrected for non-
saturable association or degradation determined in the presence of an
excess of unlabeled LDL (1 mg/mL). For analysis of FITC-LDL uptake,
CHO-ldlA7 transfected cells expressing wt LDLR were incubated for 4 h
at 37uC with 20 mg/mL of FITC-LDL as indicated. 10,000 cells were
acquired in a Facscalibur and values of LDL uptake were calculated as
described in Material and Methods. The values represent the mean of
triplicate determinations (n = 3); error bars represent 6SD. *p,0.001
compared to LDLR wt using a Student’s t-test.
doi:10.1371/journal.pone.0112677.g003
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PLOS ONE | www.plosone.org 5 November 2014 | Volume 9 | Issue 11 | e112677
and capture image acquisition with a digital camera (Axiocam
NRc5, Zeiss). Images were processed with Fluoview v.50 software.
Statistical analysis
All measurements were performed at least 3 times, with n = 3
unless otherwise stated, and results are presented as mean 6
standard deviation (S.D.). Levels of significance were determined
by a two-tailed Student’s t-test, and a confidence level of greater
than 95% (p,0.05) was used to establish statistical significance.
Results
In silico analysis
The results obtained by different software packages are
presented in Table 1.
Expression of LDLR variants in CHO-ldlA7 cells
Expression of LDLR in the CHO-ldlA7 transfected cells was
assayed by immunoblotting and qRT-PCR. As shown in
Figure 1A (upper panel), only the band corresponding to the
LDLR mature form is detected in wt LDLR and p.Val859Met
variants (Fig. 1, lanes 4 and 3, respectively); For variants
p.Val429Leu and p.Trp490Arg only the band corresponding to
the precursor form of the protein was detected (Fig. 1, lanes 2 and
7). In variants p.Ser648Pro and p.Pro685Ser both mature and
precursor forms of LDLR were detected, being the expression of
the mature protein lower compared to the wt receptor (Fig. 1,
lanes 5 and 6). The extent of protein expression was determined by
quantitative densitometric analysis using cytosolic GAPDH
protein expression as internal control (Figure 1B). LDLR mRNA
levels in the transfected cells with wt protein and LDLR variants
were determined by qRT-PCR after RNA extraction as described
in Materials and Methods. As shown in Figure 1C, the relative
LDLR mRNA expression (normalised to GAPDH) of the LDLR
variants resulted similar than the wt.
Uptake and degradation of 125I-LDL and uptake of FITC-
LDL in wt LDLR CHO-ldlA7 transfected cells
Cell lines expressing wt LDL receptor were assayed for their
ability to mediate specific, saturable uptake and degradation of
125I-LDL or FITC-LDL uptake. Cells were incubated with
labeled-LDL at different concentrations as indicated in Materials
and Methods. As shown in Fig. 2, saturable activity of LDLR was
reached at LDL concentrations above 10 mg/mL LDL for both
125I-LDL and FITC-LDL. Statistically significant values of uptake
and degradation of 125I-LDL (Fig. 2A and B) or uptake of FITC-
LDL (Fig. 2C) were determined at concentrations as low as 1 mg/
mL. Accordingly, from these results it may be inferred that LDLR
uptake activity can be determined by both methods with similar
threshold of sensitivity.
Uptake and degradation of 125I-LDL or FITC-LDL uptake
by LDLR variants in transfected CHO-ldlA7 cells
Cell lines expressing wt LDL receptor or the LDLR to
p.Val429Leu, p.Trp490Arg, p.Ser648Pro, p.Pro685Ser and
p.Val859Met variants were assayed separately by each laboratory
for their LDL uptake activities [11]. For this purpose, transfected
cells were incubated with 20 mg/mL of the corresponding labeled-
LDL for 4 h at 37uC as indicated in Materials and Methods. Cells
expressing variants p.Val429Leu and p.Trp490Arg showed
virtually no LDL uptake or degradation of 125I-LDL (Fig. 3A
and B) and did not show any statistically significant uptake of
Figure 4. Saturable binding of FITC-LDL in in CHO-ldlA7 transfected cells with wt LDLR. For analysis of FITC-LDL binding, CHO-ldlA7
transfected cells expressing wt LDLR were incubated for 4 h at 4uC with increasing concentrations of FITC-LDL as indicated. 10,000 cells were
acquired in a Facscalibur and values of LDL uptake were calculated as described in Material and Methods. The values represent the mean of triplicate
determinations (n = 3); error bars represent 6SD.
doi:10.1371/journal.pone.0112677.g004
Fluorescence-Based LDLR Functional Activity
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FITC-LDL when compared with non transfected CHO-ldlA7
cells (Fig. 3C). Cells expressing variants p.Ser648Pro and
p.Pro685Ser were impaired in both uptake and degradation,
showing only 32% and 56%, of 125I-LDL uptake capacity,
respectively, and 26% and 52% uptake of FITC-LDL, respective-
ly, when compared to cells expressing wt LDLR (Fig. 3A, and C).
p.Val859Met variant presented a similar activity than the wt, both
determined by uptake of 125I-LDL and FITC-LDL (Fig. 3A and
Figure 5. FITC-LDL binding and LDLR expression in CHO-ldlA7 transfected cells with wt or different LDLR variants. (A) For analysis of
FITC-LDL binding, CHO-ldlA7 transfected cells with different LDLR variants were incubated for 4 h at 4uC with 20 mg/mL of FITC-LDL as indicated. (B)
For analysis of LDLR expression, transfected cells were incubated for 48 h and then the LDLR expression at cellular membrane was determined as
described in Material and Methods. 10,000 cells were acquired in a Facscalibur and values of LDL uptake were calculated as described in Material and
Methods. The values represent the mean of triplicate determinations (n = 3); error bars represent 6SD. *p,0.001 compared to LDLR wt using a
Student’s t-test.
doi:10.1371/journal.pone.0112677.g005
Fluorescence-Based LDLR Functional Activity
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C). Once again, we observed similar results when comparing data
obtained by radioactivity labeling or by fluorescent labeling.
Binding of FITC-LDL to LDLR variants in CHO-ldlA7 cells
In order to explain whether the LDL uptake differences
obtained with the LDLR variants were correlated with differences
in LDL binding, we used flow cytometry to determine FITC-LDL
binding efficiency for each variant. Cells were incubated with
20 mg/mL FITC-LDL for 4 h at 4uC as described in Materials
and Methods. This LDL concentration was chosen because
binding saturation of FITC-LDL is achieved at [LDL] .10 mg/
mL (Fig. 4). As depicted in Fig. 5A the variants p.Val429Leu,
p.Trp490Arg, p.Ser648Pro and p.Pro685Ser showed a diminished
binding capacity respective to wt (wt: 10065; p.Val429Leu: 2264,
p.Trp490Arg: 5.865, p.Ser648Pro: 4865 and p.Pro685Ser:
4563) (Fig. 5A), while the binding efficiency of p.Val859Met
was similar to the wt (wt: 10065; p.Val859Met: 9563, p.0.26).
Therefore, the binding data were in agreement with the uptake
values obtained for the different LDLR variants.
Figure 6. LDLR expression of the different variants at cell surface in CHO-ldlA7 transfected cells. For confocal analysis of LDLR at cellular
membrane and LDL uptake, CHO-ldlA7 transfected cells were immunostained as described in Material and Methods with anti-hLDLR antibody and
anti-ApoB100 antibody. Texas Red and Alexa Fluor 488 labeled secondary antibodies were used to visualize LDLR or LDL, respectively. Dapi was used
to stain nuclei. The images show a representative individual cell.
doi:10.1371/journal.pone.0112677.g006
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Expression of LDLR variants in CHO-ldlA7 cells
The surface expression of the LDLR was quantified by flow
cytometry (Fig. 5B). For p.Val859Met variant the amount of
LDLR detected was very similar to the wt LDLR (wt: 10062;
p.Val859Met: 9164; p.0.15) (Fig. 5B). For p.Pro685Ser and
p.Ser648Pro variants LDLR expression was approximately the
half with respect to wt (wt: 10062; p.Pro685Ser: 4166 and
p.Ser648Pro: 5167). In the case of p.Val429Leu and
p.Trp490Arg variants there was not significant receptor expres-
sion, which agrees with the data of LDL uptake and binding
(Fig. 3 and Fig. 5A).
Figure 7. LDLR colocalization wit ER of the different variants in CHO-ldlA7 transfected cells. For confocal analysis of colocalization of
LDLR with ER, CHO-ldlA7 transfected cells were immunostained as described in Material and Methods with anti-hLDLR antibody and anti-calreticulin
antibody. Alexa Fluor 488 and Texas Red labeled secondary antibodies were used to visualize LDLR or calreticulin, respectively. The images show a
representative individual cell.
doi:10.1371/journal.pone.0112677.g007
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Intracellular localization of LDLR variants and class
mutation assignment
Confocal microscopy was used to corroborate the failure of
receptor expression or LDLR class mutation. Cells expressing wt
or LDLR variants were incubated with LDL for 4 h and then
immunostained with the appropriate antibodies to determine
LDLR and LDL localization within the cell. Texas Red or FITC-
conjugated secondary antibodies were used to visualize LDLR and
LDL, respectively. As shown in Fig. 6, p.Ser648Pro and
p.Pro685Ser variants showed a diminished receptor expression
and, p.Trp490Arg and p.Val429Leu variants did not express
significant amount of receptor. In agreement with the LDLR
expression results obtained by cytometry, confocal images of
p.Val859Met variant showed a pattern of LDLR expression
similar to the wt. Additionally, we analyzed the intracellular
localization of these variants to figure out their class defect, thus
colocalization of these variants with calreticulin, a specific marker
of the endoplasmic reticulum (ER) was assayed (Fig. 7) According
to the results, colocalization of p.Trp490Arg and p.Val429Leu
with ER indicates that these LDLR variants are class 2a mutant
receptors with a completely defective transport from the ER to the
Golgi apparatus. Regarding p.Pro685Ser and p.Ser648Pro vari-
ants, confocal images showed a partial retention of LDLR in the
ER, thus the transport to the membrane is partially blocked
indicating that these variants belong to class 2b mutant receptors.
A detailed analysis of p.Trp490Arg (Figure S2) shows that
Trp490 residing in the YWTD repeat maintains apolar interac-
tions with the surrounding amino acids which can not be
maintained when substituted by Arginine in p.Trp490Arg mutant.
Regarding p.Val429Leu, as shown in Figure S3, it is possible that
the replacement of Val by a bigger amino acid as leucine does not
allow the correct folding of two b-sheets. These effects may be
responsible of retention of the two mutants in the ER, thus causing
class 2a defects. The partial retention of LDLR in the ER
occurring in class 2b mutants p.Ser648Pro and p.Pro685Ser may
be related to structural modifications introduced by the amino acid
replacement (Figures S4 and S5). Regarding p.Ser648Pro mutant,
in wt LDLR, S648 is located in the first b-sheet of the sixth
YWTD blade, adjacent to a proline that facilitates a turn to form
the central barrel of the b-propeller. The replacement of Ser648
by Pro, leading two consecutive prolines, could disturb in someway
the structure of the b-propeller (Figure S4). Pro685, located in the
EGF-C domain of the LDL-receptor, has been identified as one of
the necessary residues involved in the packing of this domain [31].
It has been described that Pro685 establishes hydrophobic
interactions into a groove of the b-propeller with Val529 and
Tyr532. As shown in Figure S5, the replacement of Pro685 by a
serine could interfere in these interactions due to its polarity.
Discussion
CHD is the most common type of heart disease and the leading
cause of global morbidity and mortality in adults contributing to at
least one in every three deaths each year [32–34]. FH patients, if
untreated, have an increased risk of developing premature CHD
but this can be prevented by early identification and consequent
implementation of lipid lowering medication. There are a number
of criteria for diagnosing FH phenotypically in adults, but clinical
identification is not sufficient to identify a FH patient [35].
Increasing emphasis on genetic testing has become a clear
example of how new genome technologies can contribute to the
benefit of patients, but only the identification of a functional FH-
causing mutation in an individual provides a definitive diagnosis.
To date, more than 1300 genetic variants in the LDLR have been
described so far, and approximately 80–90% have been designated
as potentially pathogenic [3,10,36] although the great majority do
not have functional studies [3]. The early and definitive
identification of FH is important to improve patient prognosis
by the implementation of adequate treatment to prevent
premature CHD, especially effective in younger individuals. [37]
and, would also save large amounts of money to health services
[38].
Nowadays, studies of LDLR functionality ex vivo are carried
out mainly by radioactivity assays based on measurement of
binding, uptake and degradation of 125I-labeled LDL or by
fluorescence-based procedures. For many years the reference
method to estimate LDLR activity has been the radioactive assay
[39]. However approaches using fluorescently-labelled LDL have
also been described and allow determination of LDL binding and
uptake by flow cytometry [11,14,30]. Radioactive assay has the
advantage of being very sensitive, but it also has serious drawbacks
such as the risk of exposure to radioisotopes for experimenters and
colleagues, or the difficulties and ethical considerations of nuclear
waste elimination procedures. In contrast, the use of fluorimetric
assays based on covalent labelling of LDL with fluorophores such
as FITC overcomes many of the aforementioned problems
associated with radiolabeling. Labeling of LDL with FITC is an
inexpensive procedure, approximately 40 times cheaper than 125I-
labeling, and stable fluorophore-protein complex can be obtained,
quickly and simply and radioactivity-handling drawbacks are
avoided.
In this work we have validated the fluorimetric assay by
comparing LDLR activities of previously validated variants by the
reference method [39] with the activities of the same variants
determined by FACS. In LDLR activity characterization (binding
and uptake) by 125I-labeling and FITC-LDL, the results were very
similar, both in sensitivity as in accuracy (Fig. 2 and 4). In
addition, flow cytometry allowed the quantification of LDLR
expression at the cell surface (Fig. 4 and 5), providing a better
characterization of the defect associated to each mutation. In fact,
by complementation of flow cytometry assays with confocal
microscopy, which allows detection of the subcellular localization
of the LDLR synthesized, it is possible to assign the class type of
each variant studied.
To conclude, the data presented here show that flow cytometry
using FITC-labeled LDL is a reliable and accurate methodology to
determine LDLR activity. This method combined with the use of
confocal microscopy offers the possibility of class type assignment
for LDLR mutants, thus contributing to improve the diagnosis of
FH. In sum, fluorescence-based methodology is a highly recom-
mendable option to be used for the functional analysis of LDLR
variants before reporting any variant for genetic testing.
Furthermore, the increasing genotyping results obtained by the
next generation sequencing technique is providing a higher
number of variants that will need functional validation. Thus,
the validated methodology will be of great importance to validate
functionally the described and novel alterations in order to provide
an accurate diagnosis of FH.
Supporting Information
Figure S1 Specificity of LDLR antibody in in wt LDLR
transfected and non transfected CHO-ldlA7 cells. Cells
grown during 48 h were incubated with a mouse primary antibody
anti-LDLR or with mouse IgG2b, kappa monoclonal [MPC-11]-
isotype control as described in Materials and Methods. 10,000 cells
were acquired in a Facscalibur and values of LDL uptake were
calculated as described in Material and Methods. The values
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represent the mean of triplicate determinations (n = 3); error bars
represent 6SD. *p,0.001 compared to LDLR wt using a
Student’s t-test.
(TIF)
Figure S2 Structure of the blades maintained by the Trp
located in the YWTD repeats of the b-propeller. (A)
Hydrophobic contacts of the Trp with the surrounding residues,
and the water mediated hydrogen bound between the indol group
of tryptophan and one carboxylate group of an adjacent Asp
maintain the blade-structures. (B) Replacement of Trp490 by an
Asn impairs hydrophobic interactions. This figure was prepared
with PyMOL (DeLano scientifics) (PDB:1N7D).
(TIF)
Figure S3 Structure of the Val429 and surrounding
amino acids (A). Val429 allows the correct packing of the
structure maintaining hydrophobic contacts. Leu429 introduces
very little change in size, but maybe sufficient to impair a correct
folding of the protein (B). This figure was prepared with PyMOL
(DeLano scientifics) (PDB:1IJQ).
(TIF)
Figure S4 Structure of the b-propeller central barrel (A).
The prolines located at the beginning of each b-sheet allow a
better turn to form the barrel. Two consecutive prolines could
disturb the structure (B). This figure was prepared with PyMOL
(DeLano scientifics) (PDB:1N7D) (PDB:3S06).
(TIF)
Figure S5 Structure of the interface of b-propeller in
green and EGF-C in blue (A). Pro685 establishes hydrophobic
contacts with b-propeller. Ser685, due to its polarity could disturb
this contact (B). This figure was prepared with PyMOL (DeLano
scientifics) (PDB:1N7D) (PDB:3S06).
(TIF)
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